林业发展局接受Zircaix的申请,Zircaix是用于肾癌诊断的新成像剂。 FDA accepts application for Zircaix®, a new imaging agent for kidney cancer diagnosis.

林业发展局已接受Telix制药公司的Zircaix生物许可申请,这是肾癌的新成像剂。 The FDA has accepted Telix Pharmaceuticals' Biologics License Application for Zircaix®, a new imaging agent for kidney cancer. 如果到2025年8月27日得到批准,Zircaix将首先准确诊断和定性清晰的细胞肾脏癌,且无侵扰性。 If approved by August 27, 2025, Zircaix® will be the first to accurately diagnose and characterize clear cell renal cell carcinoma non-invasively. 根据成功的第3阶段ZIRCON研究,Zircaix表现出高度的敏感性和特殊性,有可能使肾癌管理发生革命性变化。 Based on the successful Phase 3 ZIRCON study, Zircaix® shows high sensitivity and specificity, potentially revolutionizing kidney cancer management.